Status:
COMPLETED
Dendritic Cell Vaccine Study (DC/PC3) for Prostate Cancer
Lead Sponsor:
Rockefeller University
Collaborating Sponsors:
Memorial Sloan Kettering Cancer Center
Conditions:
Prostate Cancer
Eligibility:
MALE
18+ years
Phase:
PHASE1
PHASE2
Brief Summary
The purpose of this study is to assess the safety and activity of DC/PC3, a dendritic cell vaccine used as immunotherapy for prostate cancer. The vaccine is made with each participants' own immune cel...
Detailed Description
See Brief Summary.
Eligibility Criteria
Inclusion
- Prostate cancer
- Rising prostate specific antigen (PSA, 3 values, each measured at least 2 weeks apart) post initial therapy (ie, radiation, prostatectomy) human leukocyte antigen A2.1 (HLA-A2.1)
- \-
Exclusion
- central nervous system metastasis
- History of autoimmune disease
Key Trial Info
Start Date :
June 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2015
Estimated Enrollment :
13 Patients enrolled
Trial Details
Trial ID
NCT00345293
Start Date
June 1 2006
End Date
March 1 2015
Last Update
April 18 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Rockefeller University Hospital
New York, New York, United States, 10065